"the biggest problems in drug development are not really solved by having faster access to protein structures ... we have far bigger issues with target selection (does this idea of ours really do anything against the disease, in the end?) and with unexpected toxicity (what else does our candidate do in real animals and real humans?) Those last two are where that 90% clinical failure rate comes from."